Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RENEW-MDD-1
CTR20260283Phase 3Active
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of brenipatide in major depressive disorder (MDD), sponsored by Eli Lilly and Company. Started Apr 2026; status: active.
02
Drugs
brenipatide
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on CTR20260283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260283.